Health, Body Composition, and Nutrition Research Among Women in Kazakhstan (HER-KZ)
26. Juni 2026 aktualisiert von: Mei Yen Chan, Nazarbayev University
Understanding Women's Health in Kazakhstan: Body Composition as a Key Indicator for Precision Nutrition and Predictive Healthcare
This study aims to investigate the association between dietary intake, physical activity, sleep quality, and body composition in women in Kazakhstan.
The study will recruit approximately 200 women aged 20 years and older undergoing routine DEXA examinations in Astana.
Participants will complete validated questionnaires assessing diet, physical activity, sleep quality, and sarcopenia risk, alongside functional assessments.
DEXA scans will provide measurements of fat mass, lean mass, visceral adipose tissue, bone mineral density, and appendicular skeletal muscle mass.
The primary objective is to evaluate associations between dietary quality and DEXA-derived outcomes.
Secondary objectives include assessing sarcopenia prevalence and examining relationships between physical activity, sleep quality, supplement use, and body composition.
An optional second stage will explore associations between body composition and existing inflammatory and metabolic biomarkers from medical records.
The findings are expected to provide the first comprehensive DEXA-based dataset on women's body composition and lifestyle factors in Kazakhstan and inform public health strategies.
Studienübersicht
Status
Noch keine Rekrutierung
Studientyp
Beobachtungs
Einschreibung (Geschätzt)
200
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Mei Yen Chan
- Telefonnummer: +7 7172 69 4968
- E-Mail: yen.chan@nu.edu.kz
Studieren Sie die Kontaktsicherung
- Name: Tairkhan Dautov
- E-Mail: tairkhan.dautov@gmail.com
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
N/A
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
Participants will be identified from the pool of women attending clinically-ordered DEXA examinations.
Beschreibung
Inclusion Criteria:
- Female sex
- Age ≥20 years at the time of consent
- Natural postmenopause (≥12 consecutive months of amenorrhoea not attributable to other pathological or pharmacological causes) OR surgical postmenopause (bilateral oophorectomy)
- Resident of Astana or the surrounding region with no planned relocation during the study period
- Able to provide written informed consent independently
- Able to complete the questionnaire in Kazakh, Russian, or English
Exclusion Criteria:
- Active malignancy or systemic anti-cancer treatment (chemotherapy, radiotherapy, immunotherapy) within the past 5 years
- Conditions causing secondary changes in muscle mass or body composition: hyperthyroidism (untreated), Cushing's syndrome, acromegaly, severe liver disease (Child-Pugh B or C), advanced chronic kidney disease (Stage 4 or 5, eGFR <30 ml/min/1.73 m²)
- Neuromuscular disorders that independently affect skeletal muscle mass (e.g., myopathy, motor neurone disease, multiple sclerosis)
- Long-term systemic corticosteroid therapy (>3 months in the past year, equivalent to ≥5 mg/day prednisolone)
- Severe skeletal deformity (kyphoscoliosis, limb absence) or presence of metallic implants (hip or knee prosthesis on both sides, bilateral rods) that would significantly compromise DEXA body composition validity
- Physical inability to stand or to complete the functional assessments safely
- Cognitive impairment or psychiatric condition precluding independent informed consent, as determined by the recruiting research team member
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fat Mass Index (FMI)
Zeitfenster: Assessed at a single study visit during enrollment
|
FMI in kg/m², measured by dual-energy X-ray absorptiometry (DEXA).
Higher values indicate greater adiposity and a less favorable body composition profile.
|
Assessed at a single study visit during enrollment
|
|
Bone mineral density (BMD)
Zeitfenster: Assessed at a single study visit during enrollment
|
BMD in g/cm², measured using dual-energy X-ray absorptiometry (DEXA).
Higher values indicate greater bone mineral density and generally better bone health, whereas lower values indicate reduced bone mineral density.
|
Assessed at a single study visit during enrollment
|
|
Fat-Free Mass Index (FFMI)
Zeitfenster: Assessed at a single study visit during enrollment
|
FFMI in kg/m², calculated as total fat-free mass (kg) divided by height squared (m²), and measured using dual-energy X-ray absorptiometry (DEXA).
Higher values indicate greater fat-free mass relative to height and a more favorable body composition profile.
|
Assessed at a single study visit during enrollment
|
|
Visceral Adipose Tissue (VAT)
Zeitfenster: Assessed at a single study visit during enrollment
|
Measured using dual-energy X-ray absorptiometry (DEXA) and reported as visceral fat mass in grams (g) or kilograms (kg).
Higher values indicate greater accumulation of visceral adipose tissue and a less favorable body composition profile.
|
Assessed at a single study visit during enrollment
|
|
Appendicular lean mass index (ALMI)
Zeitfenster: Assessed at a single study visit during enrollment
|
ALMI in kg/m², calculated as the sum of lean mass from both arms and legs (kg) divided by height squared (m²), and measured by dual-energy X-ray absorptiometry (DEXA).
This is a continuous measure and does not have a predefined minimum or maximum value.
Higher values indicate greater appendicular lean mass.
|
Assessed at a single study visit during enrollment
|
|
Appendicular skeletal muscle mass and index (ASMI)
Zeitfenster: Assessed at a single study visit during enrollment
|
ASMI in kg/m², calculated as the appendicular skeletal muscle mass (sum of lean soft tissue mass of the arms and legs, kg) divided by height squared (m²), and measured using dual-energy X-ray absorptiometry (DEXA).
This is a continuous measure and has no predefined minimum or maximum value.
Higher values indicate greater appendicular skeletal muscle mass.
|
Assessed at a single study visit during enrollment
|
|
Body Mass Index (BMI)
Zeitfenster: Assessed at a single study visit during enrollment
|
Assessed at a single study visit during enrollment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
SARC-F Score
Zeitfenster: Assessed at a single study visit during enrollment
|
A self-reported screening tool consisting of five items evaluating strength, assistance with walking, rising from a chair, climbing stairs, and falls.
Each item is scored from 0 to 2, yielding a total score ranging from 0 to 10. Higher scores indicate greater risk of sarcopenia and poorer physical function, with scores ≥4 suggesting probable sarcopenia.
|
Assessed at a single study visit during enrollment
|
|
Rapid Eating Assessment for Participants - dietary quality score
Zeitfenster: Assessed at a single study visit during enrollment
|
A 19-item questionnaire evaluating food sufficiency, healthy eating patterns, foods to limit, salt intake, alcohol consumption, and dietary supplement use.
Each item is rated on a 4-point frequency scale.
Responses are summed to generate a total dietary quality score ranging from 19 to 76, with higher scores indicating better overall dietary quality and greater adherence to healthy dietary practices.
|
Assessed at a single study visit during enrollment
|
|
IPAQ-SF Physical Activity (International Physical Activity Questionnaire - Short Form)
Zeitfenster: Assessed at a single study visit during enrollment
|
Evaluates the frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity over the past 7 days.
Responses are converted into metabolic equivalent task (MET)-minutes per week.
Total physical activity score has no fixed minimum or maximum value, as it is a continuous measure.
Higher scores indicate greater levels of physical activity.
|
Assessed at a single study visit during enrollment
|
|
Pittsburgh Sleep Quality Index (PSQI) Global Score
Zeitfenster: Assessed at a single study visit during enrollment
|
A 19-item questionnaire that evaluates sleep quality and disturbances over the past month across seven components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction).
Each component is scored from 0 to 3, yielding a total global score ranging from 0 to 21.
Higher scores indicate poorer sleep quality, with scores >5 generally indicating poor sleep quality.
|
Assessed at a single study visit during enrollment
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Juli 2026
Primärer Abschluss (Geschätzt)
1. Juli 2029
Studienabschluss (Geschätzt)
1. Juli 2029
Studienanmeldedaten
Zuerst eingereicht
18. Juni 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
26. Juni 2026
Zuerst gepostet (Tatsächlich)
30. Juni 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
30. Juni 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
26. Juni 2026
Zuletzt verifiziert
1. Juni 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Physische Aktivität
-
Affiliated Hospital to Academy of Military Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University...RekrutierungAltersspanne ≥16 Jahre, Geschlecht unbegrenzt | Histopathologie bestätigtes diffuses großzelliges B-Zell-Lymphom oder hochgradiges B-Zell-Lymphom | Erhaltene vorherige Erstlinien-Chemotherapie für DLBCL oder HGBL, CR für vier Zyklen nicht erreicht oder rezidiviert | Mindestens eine... und andere BedingungenChina